ASH 2018 | Progression risk-based classification for smoldering Waldenström’s macroglobulinemia

Mark Bustoros

Smoldering Waldenström’s macroglobulinemia (SWM) is the ideal stage to treat the disease and prevent progression to Waldenström’s macroglobulinemia (WM). Here, Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the development of a classification system based on the risk of progression from asymptomatic SWM to symptomatic WM. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Bustoros explains how this will allow for the stratification of SWM patients into low-, intermediate- and high-risk groups, allowing the identification of patients who might benefit from early intervention in this rare malignancy.

Share this video